|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multiple-dose pharmacokineties and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study 显示文摘 | Hussey EK Dobbins RL Stoltz RR | 2010 | J Clin Pharmancol2010，50，6： | 1 |
| 2 | 雷夫康唑治疗甲真菌病的疗效、安全性和药代动力学研究显示文摘雷夫康唑是近年研发的第二代三唑类抗真菌药,比第一代的同类药物伊曲康唑,氟康唑等的抗菌谱更为广泛。加拿大多伦多大学Sunnybrook和Women’s College Health Science Centre皮肤科的Gupta教授在该药的Ⅰ/Ⅱ期临床试验中.通过随机双盲双模拟安慰剂对照研究比较了不同剂量雷夫康唑治疗甲真菌病的疗效和安全性。 | Gupta AK Leonardi C Stoltz RR 尚淑贤(摘) | 2006 | 国际皮肤性病学杂志2006，32，4： | 1 |
| 3 | Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects显示文摘 | Stoltz RR Harris SI Kuss ME | 2002 | Am J Gastro-enterol2002，97，1： | 1 |
| 4 | Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects 显示文摘 | Stoltz RR Harris SI Kuss ME | 2002 | Am J Gastroenterol2002，97，： | 1 |
| 5 | Pareeoxih sodium demonstrates gastrointestinal satety eomparahle to placebo in healthy suhjects显示文摘 | Harris SI Stoltz RR Le Comte D | 2004 | J Clin Gastroentero12004，38，： | 1 |
| 6 | Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects 显示文摘 | Stoltz RR Harris SI Kuss ME | 2002 | Am J Gastroenterol2002，97，1： | 1 |
| 7 | Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects显示文摘 | Stoltz RR Harris SI Kuss ME | 2002 | Am J Gastroenterol2002，97，： | 1 |
| 8 | Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects 显示文摘 | STOLTZ RR HARRIS SI KUSS ME | 2002 | Am J Gastroenterol2002，97，1： | 1 |
| 9 | Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects 显示文摘 | Harris SI Kuss ME | 2002 | Am J Gastroenterol2002，97，1： | 1 |
| 10 | Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects显示文摘 | Stoltz RR Harris SI Kuss ME | 2002 | Am J Gastroenterol2002，97，1： | 1 |
| 11 | A phase lflI randomized, double-blind,placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis 显示文摘 | Gupta AK Leonardi C Stoltz RR | 2005 | J Eur Acad Dermatol Venereol2005，19，4： | 1 |
| 12 | Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate,a novel inhibitor of glucose reabsorption,in healthy overweight and obese subjects:a randomized doubleblind study显示文摘 | Hussey EK Dobbins RL Stoltz RR | 2010 | Clin Pharmacol2010，50，6： | 1 |
| 13 | Parecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects显示文摘 | Harris SI Stoltz RR LeComte D | 2004 | Clin Gastroenterol2004，38，7： | 1 |
| 14 | Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects显示文摘 | Stoltz RR Harris SI Kuss ME | 2002 | Am J Gastroenterol2002，97，1： | 1 |
| 15 | Parecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthysubjects 显示文摘 | Harris SI Stoltz RR LeComte D | 2004 | Clin Gastroenterol2004，38，7： | 1 |
| 16 | Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects显示文摘 | Stoltz RR Harris SI Kuss ME | 2002 | Am-J-Gastroenterol2002，97，1： | 1 |
| 17 | A phase I/II randomized, double-blind, placebo-controlled,dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis显示文摘 | Gupta AK Leonardi C Stoltz RR | 2005 | J Eur Acad Dermatol Venereol2005，19，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员